variant_name	variant_aliases	variant_type	variant_clinvar_entries	variant_entrez_id	variant_entrez_name	variant_hgvs_expressions	variant_groups	gene_name	gene_aliases	gene_description	gene_entrez_id	gene_source	mol_profile_name	mol_profile_definition	mol_profile_score	assertion_name	assertion_acmg_codes	assertion_amp_level	assertion_direction	assertion_type	assertion_description	assertion_disease	assertion_phenotypes	assertion_significance	assertion_status	assertion_summary	assertion_therapies	assertion_therapy_interaction_type	assertion_variant_origin	evidence_name	evidence_description	evidence_disease	evidence_level	evidence_support	evidence_type	evidence_phenotypes	evidence_rating	evidence_significance	evidence_source	evidence_status	evidence_therapies	evidence_therapy_interaction_type
M918T	['MET918THR', 'RS74799832']	['Missense Variant']	['13919']	5979	RET	['NM_020975.4:c.2753T>C', 'NP_065681.1:p.Met918Thr', 'ENST00000355710.3:c.2753T>C', 'NC_000010.10:g.43617416T>C']	['RET Motesanib Resistance']	RET	['CDHF12', 'CDHR16', 'HSCR1', 'MEN2A', 'MEN2B', 'MTC1', 'PTC', 'RET', 'RET-ELE1']	RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.	5979	['Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.', 'Targeted therapy: a new hope for thyroid carcinomas.']	RET M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	86.0																											
V104M	['VAL104MET']	['Missense Variant']	['376410']	2065	ERBB3	['NC_000012.11:g.56478854G>A']	[]	ERBB3	['ERBB3', 'ErbB-3', 'FERLK', 'HER3', 'LCCS2', 'MDA-BF-1', 'VSCN1', 'c-erbB-3', 'c-erbB3', 'erbB3-S', 'p180-ErbB3', 'p45-sErbB3', 'p85-sErbB3']		2065	[]	ERBB3 V104M		15.0																											
Q1178*	['Q1178X', 'GLN1178TER', 'RS45517297']	['Stop Gained']	['49263']	7249	TSC2	['NM_000548.4:c.3532C>T', 'NP_000539.2:p.Gln1178Ter', 'ENST00000219476.3:c.3532C>T', 'NC_000016.9:g.2130300C>T']	[]	TSC2	['LAM', 'PPP1R160', 'TSC2', 'TSC4']		7249	[]	TSC2 Q1178*		12.5																											
ALK Fusion F1245C	['RS863225283', 'ALK FUSION PHE1245CYS']	['Missense Variant', 'Transcript Fusion']	['217856']	238	ALK	['NM_004304.4:c.3734T>G', 'NP_004295.2:p.Phe1245Cys', 'NC_000002.11:g.29436859A>C', 'ENST00000389048.3:c.3734T>G']	[]	ALK	['ALK', 'ALK1', 'CD246', 'NBLST3']	ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.	238	['ALK inhibitors and advanced non-small cell lung cancer (review).', 'ALK in lung cancer: past, present, and future.']	ALK ALK Fusion F1245C	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.	14.5																											
EML4::ALK  V1180L	['EML4-ALK VAL1180LEU', 'EML4-ALK  V1180L']	['Missense Variant', 'Transcript Fusion']	['NONE FOUND']	238	ALK	['ENST00000389048.3:c.3538G>C', 'NC_000002.11:g.29443679C>G', 'NP_004295.2:p.Val1180Leu', 'NM_004304.5:c.3538G>C']	[]	ALK	['ALK', 'ALK1', 'CD246', 'NBLST3']	ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.	238	['ALK inhibitors and advanced non-small cell lung cancer (review).', 'ALK in lung cancer: past, present, and future.']	ALK EML4::ALK  V1180L	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.	13.0																											
E322K	['GLU322LYS']	['Missense Variant', 'Gain Of Function Variant']	['376450']	5594	MAPK1	['ENST00000215832.6:c.964G>A', 'NC_000002.11:g.22127164C>T', 'NP_002736.3:p.Glu322Lys', 'NM_002745.4:c.964G>A']	[]	MAPK1	['ERK', 'ERK-2', 'ERK2', 'ERT1', 'MAPK1', 'MAPK2', 'NS13', 'P42MAPK', 'PRKM1', 'PRKM2', 'p38', 'p40', 'p41', 'p41mapk', 'p42-MAPK']		5594	[]	MAPK1 E322K		10.0																											
C134W	[]	['Missense Variant']	[]	668	FOXL2	['NC_000003.11:g.138665163G>C']	[]	FOXL2	['BPES', 'BPES1', 'FOXL2', 'PFRK', 'PINTO', 'POF3']		668	[]	FOXL2 C134W	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.	70.0																											
G469A	['RS121913355', 'GLY469ALA']	['Missense Variant']	['13971']	673	BRAF	['NM_004333.4:c.1406G>C', 'NP_004324.2:p.Gly469Ala', 'NC_000007.13:g.140481402C>G', 'ENST00000288602.6:c.1406G>C']	[]	BRAF	['B-RAF1', 'B-raf', 'BRAF', 'BRAF-1', 'BRAF1', 'NS7', 'RAFB1']	"BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.

Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.
Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.
Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.
Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase."	673	['Targeting of the BRAF gene in papillary thyroid carcinoma (review).', 'Clinicopathological relevance of BRAF mutations in human cancer.', 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.']	BRAF G469A		5.0																											
N546K	['ASN546LYS', 'RS779707422']	['Missense Variant']	['224896']	2260	FGFR1	['NM_023110.2:c.1638C>A', 'NP_075598.2:p.Asn546Lys', 'ENST00000341462.5:c.1638C>A', 'NC_000008.10:g.38274849G>T']	[]	FGFR1	['BFGFR', 'CD331', 'CEK', 'ECCL', 'FGFBR', 'FGFR-1', 'FGFR1', 'FLG', 'FLT-2', 'FLT2', 'HBGFR', 'HH2', 'HRTFDS', 'KAL2', 'N-SAM', 'OGD', 'bFGF-R-1']	"FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. 
FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways (Turner et. al.).
Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression (Marshall et. al,  Weiss et. al.,  Cheng et. al.).
Especially amplification of FGFR1 in lung cancer is an emerging treatment target with clinical studies currently ongoing (e.g. NCT01004224). However, FGFR1 amplification does not always correlate with protein expression and predictive biomarkers still remain to be defined in clinic (von MÃ¤ssenhausen et. al.).
Mutation of FGFR1 seems to be less common, but has been described in glioblastoma, pilocytic astrocytomas and Ewing's sarcoma (Rand et. al., Jones et. al., Agelopoulos et. al.)."	2260	['Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.', 'Fibroblast growth factor signalling: from development to cancer.', 'Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.', 'Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.', 'FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area.', 'Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.', 'Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.', 'Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.']	FGFR1 N546K		8.0																											
F877L	['PHE877LEU']	['Missense Variant']	['376347']	367	AR	['ENST00000374690.3:c.2629T>C', 'NC_000023.10:g.66943549T>C', 'NM_000044.4:c.2629T>C', 'NP_000035.2:p.Phe877Leu']	[]	AR	['AIS', 'AR', 'AR8', 'DHTR', 'HUMARA', 'HYSP1', 'KD', 'NR3C4', 'SBMA', 'SMAX1', 'TFM']		367	[]	AR F877L		4.0																											
